Post-Exposure Intradermal Antirabies Vaccine: A Cheaper Alternative for Developing Countries
- 1 April 1984
- journal article
- Published by SAGE Publications in Tropical Doctor
- Vol. 14 (2), 67-70
- https://doi.org/10.1177/004947558401400206
Abstract
Intradermal (i.d.) human diploid-cell vaccine (HDCV) has been routinely used for post-exposure treatment of rabies at a rural mission hospital in central Thailand since 1979. Four 0.1 ml doses have been given over a fortnight, reconstituted vaccine being regularly stored for repeated use. No significant side effects have been encountered. Consistent antibody formation has been shown. In patients followed up for one year no case of rabies has been observed. Post-exposure intradermal HDCV is safer and more effective than nervous tissue vaccine and is of moderate cost. It should be more widely employed within the Third World.Keywords
This publication has 11 references indexed in Scilit:
- AN ECONOMICAL REGIMEN OF HUMAN DIPLOID CELL STRAIN ANTI-RABIES VACCINE FOR POST-EXPOSURE PROPHYLAXISThe Lancet, 1983
- STABILITY OF HUMAN DIPLOID-CELL-STRAIN RABIES VACCINE AT HIGH AMBIENT TEMPERATURESThe Lancet, 1983
- HUMAN RABIES AFTER LATE ADMINISTRATION OF HUMAN DIPLOID CELL VACCINE WITHOUT HYPERIMMUNE SERUMThe Lancet, 1982
- Brief Review of Diagnosis, Management and Immunotherapy of RabiesTropical Doctor, 1982
- MULTISITE INTRADERMAL ANTIRABIES VACCINATIONThe Lancet, 1981
- Intradermal Immunization With Rabies VaccinePublished by American Medical Association (AMA) ,1980
- Postexposure Trial of a Human Diploid Cell Strain Rabies VaccineThe Journal of Infectious Diseases, 1980
- CURRENT STATUS OF RABIES PROBLEMS IN THAILANDJapanese Journal of Medical Science and Biology, 1979
- HUMAN DIPLOID CELL STRAIN RABIES VACCINEThe Lancet, 1976
- IMMUNOGENICITY AND ACCEPTABILITY OF A HUMAN DIPLOID-CELL CULTURE RABIES VACCINE IN VOLUNTEERSThe Lancet, 1975